trending Market Intelligence /marketintelligence/en/news-insights/trending/isFbj7O5u42INNNtBmUVZA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Melinta Therapeutics interim CEO to assume permanent role

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Melinta Therapeutics interim CEO to assume permanent role

Melinta Therapeutics Inc. said John Johnson agreed to become the company's permanent CEO.

Johnson, who is a director of the New Haven, Conn.-based pharmaceutical company, has served as interim CEO since Oct. 22. He filled in for Dan Wechsler, who stepped down to pursue other opportunities.

The appointment is subject to the close of a previously announced commitment for a credit facility of up to $135 million from its largest shareholder, Vatera Healthcare Partners LLC.